Merck Raises Revenue Forecast to $70 Billion by Mid-2030s
Merck has announced an increase in its revenue forecast for new growth drivers to $70 billion by the mid-2030s. This revision reflects the company's strategy to diversify its revenue streams and accelerate drug launches ahead of competition to its cancer therapy Keytruda.
Insights:
Merck & Co., Inc. announced on January 12, 2026, a substantial upward revision to its revenue forecast for new growth drivers, projecting $70 billion by the mid-2030s. This announcement underscores Merck's strategic shift towards diversifying its revenue streams and accelerating drug launches in response to anticipated competition to its blockbuster cancer therapy, Keytruda.
